Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution

Circulation. 2018 Aug 14;138(7):743-745. doi: 10.1161/CIRCULATIONAHA.118.035898.

Céline Anquetil^{1

2}, Joe-Elie Salem^{3

4}, Bénédicte Lebrun-Vignes³, Douglas B Johnson⁵, Andrew L Mammen^{6

7}, Werner Stenzel^{4

8}, Sarah Léonard-Louis⁹, Olivier Benveniste^{1

2}, Javid J Moslehi^{4

5}, Yves Allenbach^{1

2}

¹ Department of Internal Medicine and Clinical Immunology (C.A., O.B., Y.A.).
² Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Centre de Recherche en Myologie, UMRS974, Paris, France (C.A., O.B., Y.A.).
³ Department of Pharmacology, Regional Center of Pharmacovigilance (J.-E.S., B.L.-V.), Sorbonne Universités, Pitié-Salpêtrière University Hospital, Paris, France.
⁴ Division of Cardiovascular Medicine and Cardio-Oncology Program, Department of Medicine (J.-E.S., W.S., J.J.M.).
⁵ Division of Oncology, Department of Medicine (D.B.J., J.J.M.), Vanderbilt University Medical Center, Nashville, TN.
⁶ Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Expression, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD (A.L.M.).
⁷ Department of Neurology and Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD (A.L.M.).
⁸ Departments of Neuropathology, Charité-Universitätsmedizin, Berlin, Germany (W.S.).
⁹ Department of Neuropathology (S.L.-L.).

No abstract available

Keywords: antineoplastic agent, immunological; autoimmune diseases; myasthenia gravis; myocarditis; myositis.

Publication types